Short answer
Johnson & Johnson (JNJ) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Jennifer Taubert retiring September 1, 2026 as Executive Vice President and Worldwide Chairman, Innovative Medicine.
Johnson & Johnson 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Jennifer Taubert retiring September 1, 2026 as Executive Vice President and Worldwide Chairman, Innovative Medicine
- Departure also removes Taubert from Johnson & Johnson’s Executive Committee
- Leadership transition affects the company’s Innovative Medicine segment, a key pharmaceutical business
- Exhibit 99.1 contains the company’s related announcement
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Johnson & Johnson 8-K filings
Get the next JNJ 8-K as it lands
Follow JNJ for push alerts, or ask the research agent what this filing means.